Who Supplies Ibrutinib to India from UNITED KINGDOM

Importing finished pharmaceutical formulations containing Ibrutinib into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each batch of the formulation must be accompanied by a Certificate of Pharmaceutical Product (CoPP) issued by the manufacturer, ensuring adherence to Good Manufacturing Practices (GMP). The formulation must also be registered with the CDSCO, which involves submitting Form CT-20/40/41, along with stability data demonstrating compliance with International Council for Harmonisation (ICH) guidelines for Zone IV conditions. The registration process typically takes 6 to 12 months, depending on the completeness of the submitted documentation and the CDSCO's evaluation timeline.

Upon arrival in India, each batch of Ibrutinib formulations is subject to quality testing by CDSCO-approved laboratories. The batch must be accompanied by a Certificate of Analysis (CoA) from the manufacturer, detailing the formulation's composition, potency, and compliance with specified standards. Stability data, including accelerated and long-term studies, must be provided to confirm the formulation's shelf-life under Indian climatic conditions. The formulation must meet the standards set forth in the Indian Pharmacopoeia. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported formulations.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, has led to increased scrutiny of imported formulations, with a focus on encouraging self-reliance. Bilateral agreements between India and the United Kingdom have facilitated smoother trade relations, including mutual recognition of GMP certifications, thereby streamlining the import process for formulations containing Ibrutinib.

India imports finished Ibrutinib formulations primarily due to the presence of patented or branded formulations not manufactured domestically. Specific dosage forms, such as certain tablet strengths or combination therapies, may not be produced locally, necessitating imports. While India has a robust pharmaceutical manufacturing sector, the demand for imported Ibrutinib formulations indicates a gap in domestic production capabilities for certain specialized products. The market size for Ibrutinib formulations in India is substantial, with imports contributing to a significant portion of the total market value.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the imported value. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is levied. The total landed duty percentage, combining BCD, IGST, and SWS, amounts to approximately 32.2%. Anti-dumping duties are not currently applicable to Ibrutinib formulations. Exemption notifications may apply under specific conditions, such as for formulations intended for government procurement or public health programs.

India sources finished Ibrutinib formulations from the United Kingdom due to the presence of patented formulations and specialized dosage forms not available domestically. The United Kingdom's pharmaceutical industry is known for its high-quality standards and adherence to international regulatory requirements, providing a competitive advantage in the Indian market. Other suppliers, such as China, Germany, and the United States, also export Ibrutinib formulations to India; however, the United Kingdom's share in this segment remains significant due to its established trade relations and product offerings.

India imports finished Ibrutinib formulations from the United Kingdom due to the availability of patented formulations and specialized dosage forms not produced domestically. The United Kingdom's pharmaceutical industry offers high-quality products that meet international standards, providing a reliable source for formulations containing Ibrutinib. Specific formulations, such as certain tablet strengths or combination therapies, may not be manufactured in India, necessitating imports to meet patient needs.

When compared to other origins like China, Germany, and the United States, the United Kingdom offers a competitive advantage in terms of product quality, regulatory compliance, and established trade relations with India. While other countries may offer lower prices, the United Kingdom's adherence to stringent quality standards and its reputation in the pharmaceutical industry make it a preferred source for formulations containing Ibrutinib.

Indian importers face several supply chain risks when sourcing finished Ibrutinib formulations from the United Kingdom, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or regulatory delays; therefore, maintaining a diversified supplier base and robust risk management strategies is essential to mitigate these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and inventory management.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments of their manufacturing facilities, quality control processes, and regulatory compliance history.

1. DGFT Importer Exporter Code (IEC): Ob